Medication info
Valsartan Tablet 80 mg

Valsartan Tablet 80 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pale red round film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201105143 · Notified 2011.08.09 · Insurance code 642506610

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during or between meals. It is recommended to take the medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: The daily dose of this drug for patients with mild to moderate hepatic impairment should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is primarily used to control blood pressure in patients with essential hypertension. It is also helpful for heart failure patients who are intolerant to ACE inhibitors, particularly those classified as NYHA class II to IV. After a myocardial infarction, it is effective in reducing mortality risk in patients with impaired left ventricular function. This medication contributes to improving cardiovascular health and enhancing the quality of life for patients. Therefore, it is used for the management of essential hypertension, heart failure, and post-myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during or between meals. It is recommended to take the medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: The daily dose of this drug for patients with mild to moderate hepatic impairment should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.

Precautions

This medication may cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Women who are pregnant, possibly pregnant, or breastfeeding should not take this medication. It is also not safe for patients with severe liver impairment or cirrhosis. Patients with severely impaired kidney function or certain hereditary angioedema should not take this medication. Caution is advised for elderly patients, patients with high serum potassium levels, and patients with mild to moderate liver impairment. Special care is required for patients with heart disease or renal artery stenosis when administering this medication. This medication can cause a rapid drop in blood pressure when first administered, especially in patients who are deficient in fluids or sodium, so it should be started at a low dose and gradually increased. If blood pressure drops too low, the patient should be laid down and, if necessary, normal saline should be administered to stabilize blood pressure. Side effects such as headache, dizziness, fatigue, and cough may occur during treatment, and in severe cases, a doctor should be consulted immediately. Particularly, regular checks on kidney function or serum potassium levels should be conducted, and appropriate action should be taken if abnormalities are detected. Caution should be exercised for drug interactions when taken with other antihypertensive drugs, diuretics, or potassium-sparing agents, and it should be taken according to the physician's instructions. The safety and efficacy of this medication have not been established in children and adolescents, so it is advisable not to use it in patients under 18 years of age. In the case of overdose, symptoms such as hypotension and decreased consciousness may occur, and immediate medical attention should be sought. This medication should be stored out of reach of children, and transferring it to other containers should be avoided. Caution is required when driving or operating machinery as dizziness may occur.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering and kept in a cool place below 30 degrees Celsius.

Appearance and packaging

Appearance

Pale red round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.